Novel approaches to the treatment of acute renal failure

Expert Opinion on Investigational Drugs

Volumn 9, Issue 11, 2000, Pages 2579-2592

  Venkataraman, R ^a   Kellum, J A ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Acute renal failure; Adenosine receptor blockers; Atrial natriuretic peptide analogues; Calcium channel blockers; Dopamine receptor agonists; Endothelin receptor antagonists; Growth factors

Indexed keywords

ACETYLCYSTEINE; ADENOSINE RECEPTOR BLOCKING AGENT; ANARITIDE; ATRIAL NATRIURETIC FACTOR; CALCIUM ANTAGONIST; CREATININE; CYCLOSPORIN A; DILTIAZEM; DOPAMINE RECEPTOR STIMULATING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; FENOLDOPAM; GROWTH FACTOR; ISRADIPINE; LAZAROID; NIFEDIPINE; NITRIC OXIDE; PLACEBO; THEOPHYLLINE; URODILATIN; VERAPAMIL;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADRENAL MEDULLA; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIURESIS; DRUG EFFICACY; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HUMAN; HYDRATION; HYPOTENSION; HYPOXIA; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; NATRIURESIS; NONHUMAN; OXYGEN CONSUMPTION; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW;

EID: 0033767589     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.11.2579     Document Type: Review

References (129)

1. Acute renal failure: Definition and pathogenesis
2. Hospital-acquired renal insufficiency: A prospective study
3. French Study Group On Acute Renal Failure: Acute renal failure in intensive care units - Causes, outcomes and prognostic factors of hospital mortality: A prospective multicenter study
4. The changing pattern of severe acute renal failure
5. Transport activity modifies the ascending limb damage in isolated perfused kidney
6. Diuretics in acute renal failure
7. Use of diuretics in the acute care setting
8. Experimental acute renal failure
9. Pathophysiology of acute renal failure
10. Lower nephron nephrosis
11. The pathogenesis of acute renal failure associated with traumatic and toxic injury
12. Transport-dependent anoxic cell injury in the isolated rat perfused kidney
13. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat
14. The role of medullary ischemia in acute renal failure
15. Differential structure-activating relationships of atrial peptides as natriuretics and renal vasodilators in the dog
16. Specific membrane receptors for atrial natriuretic peptides in renal and vascular tissues
17. Renal and systemic hemodynamic effects of synthetic atrial natriuretic peptide in anesthetized rat
18. +-transport in medullary collecting duct
19. Norepinephrine induced acute renal failures; beneficial effects of atrial natriuretic factor
20. In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure
21. Atrial Natriuretic peptide and dopamine in a rat model of ischemic acute renal failure
22. Renal actions of atrial natriuretic peptide on the post-ischemic kidney
23. Beneficial effect of the ANP analog, A68828 on recovery from ischemic acute renal failure
24. Beneficial effects of atrial natriuretic factor on cisplatin-induced acute renal failure
25. Prevention of acute cyclosporine nephrotoxicity by atrial natriuretic factor after ischemia in the rat
26. Atrial natriuretic peptide in gentamicin-induced acute renal failure
27. Effect of atriopeptin II on contrast medium-induced changes in renal blood flow
28. Effects of atrial natriuretic peptide in clinical acute renal failure
29. Anaritide in ATN. (Auriculin anaritide ARF study group)
30. Update on clinical trials with atrial natriuretic peptide in acute tubular necrosis
31. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy
32. Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after cardiac surgery
33. Atrial natriuretic factor does not improve the outcome of cadaveric renal transplantation
34. Impaired response to intra-renal administration of atrial natriuretic peptide in ischemic acute renal failure of a transplant patient
35. Urodilantin, a natriuretic factor from kidneys can modify renal and cardiovascular system in men
36. Urodilantin: A new peptide with beneficial effects in post-operative therapy of cardiac transplant recipients
37. Acute renal failure following cardiac surgery is reverted by administration of urodilantin (INN: Ularitide)
38. Urodilantin: A new approach for treatment of therapy-resistant acute renal failure after liver transplantation
39. Therapeutic use of natriuretic peptide ularitide in acute renal failure
40. Natriuretic peptides and acute renal failure
41. Adenosine and tubuloglomerular feedback
42. Synergistic effects of angiotensin and adenosine in the renal microvasculature
43. Role for intrarenal adenosine in the renal hemodynaimc response to contrast media
44. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application
45. The non-selective adenosine antagonist theophylline does prevent renal dysfunction induced by radiocontrast agents
46. Prevention of radiocontrast media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with adenosine-antagonist theophylline
47. The use of diuretics and dopamine in acute renal failure: A systematic review of the evidence
48. Locally formed dopamine inhibits Na-K ATPase activity in rat renal cortical tubule cells
49. Dopamine increases renal medullary blood flow without improving regional hypoxia
50. Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man
51. 'Renal-dose' dopamine for the treatment of acute renal failure: Scientific rationale, experimental studies and clinical trials
52. Renal effects of dopamine
53. Preventing renal failure in critically ill patients
54. Effects of dopamine receptor agonist on cardiovascular and renal function
55. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics
56. Characterization of the peripheral and central effects of SK and F 82526, a novel dopamine receptor agonist
57. The effect of oral fenoldopam (SK and F 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man
58. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension
59. Effect of SK and F 82526 on renal vascular resistance following acute myocardial infarction in the dog
60. Fenoldopam reverses cyclosporine-A induced renal vasoconstriction in kidney transplant recipients
61. Effect of fenoldopam on the acute and subacute nephrotoxic renal failure produced by amphotericin B in the dog
62. Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension
63. Fenoldopam but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function
64. Fenoldopam improves renal dysfunction secondary to ventilation with PEEP
65. Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure
66. Selective dopamine receptor-1 stimulation with fenoldopam in cirrhotic patients with ascites: A systemic, splanchnic and renal hemodynamic study
67. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects
68. Cellular calcium in ischemic acute renal failure
69. The effects of diltiazem and captopril on glycerol-induced acute renal failure in the rat: Function, pathologic and microangiographic studies
70. Calcium-channel blockade in experimental; aminoglycoside nephrotoxicity
71. The effect of preventive administration of verapamil on ischemic renal failure in dogs
72. Calcium antagonists and the kidney: Future therapeutic perspectives
73. Natriuretic effects of calcium antagonists in humans: A review of experimental evidence and clinical data
74. Are there differences in the renal effects of calcium antagonists?
75. A role for calcium in radiocontrast induced reductions in renal hemodynamics
76. Prevention of radiocontrast-induced nephrotoxicity by the calcium-channel blocker nitrendipine: A prospective, randomized clinical trial
77. Randomized prospective study on renal effects of two different contrast media in humans: Protective role of calcium-channel blocker
78. Calcium-channel blockers for prophylaxis of radiocontrast associated nephrotoxicity
79. Verapamil prevents post-transplant oliguric renal failure
80. Prevention of post-transplant acute tubular necrosis by calcium antagonist diltiazem: A prospective randomized study
81. Prevention of delayed graft dysfunction in cadaver kidney transplantation by diltiazem: Outcome of two prospective, randomized, clinical trials
82. Kidney graft pretreatment by diltiazem reduces the rate of acute renal failure after transplantation
83. Effects of calcium antagonists in ameliorating cyclosporine A nephrotoxicity and post-transplant acute tubular necrosis
84. Effect of calcium-antagonist on renal graft function
85. Reversal of renal and smooth muscle actions of thromboxane mimetic U-44069 by diltiazem
86. Prevention of acute cyclosporine-induced renal blood flow inhibition and improved immunosuppression with verapamil
87. Effects of isradipine on renal function in cyclosporine-treated renal transplanted patients
88. Protective effects of diltiazem and prostacycline analogue iloprost in human renal transplantation
89. Addition of Isradipine (lomir) results in a better renal function after kidney transplantation: A double-blind, randomized, placebo-controlled, multi-center study
90. Effect of endothelin on regional hemodynamics and renal function in awake normotensive rats
91. Influence of the renal endothelin system on the autoregulation of renal blood flow in spontaneously hypertensive rats
92. Glomerular actions of endothelin in vivo
93. Plasma endothelin levels in acute renal failure
94. Pathophysiological role of endothelin in acute renal failure
95. Endothelin: A potent renal and systemic vasoconstrictor peptide
96. Radiocontrast increases plasma and urinary endothelin-1.
97. The pathophysiological role of endothelin in acute vascular rejection after renal transplantation
98. The renoprotective potential of endothelin receptor antagonists
99. Reversal of post-ischemic acute renal failure with a selective endothelin-A receptor antagonist in the rat
100. Effect of and endothelin-receptor antagonist on ischemic acute renal failure
101. Effects of endothelin-receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles
102. Prevention of cyclosporine A induced renal vasoconstriction by endothelin receptor antagonist SB 209670
103. Radiocontrast agents induce endothelin release in vivo and in vitro
104. Beneficial effect of ETA receptor blockade in radiocontrast-induced nephropathy in the rat
105. Targets for endothelin in the diseased kidney: Clues for therapeutical intervention
106. Oxidant mechanisms in toxic acute renal failure
107. Radiocontrast medium-induced declines in renal function: A role for oxygen free radicals
108. N-acetylcysteine ameliorates ischemic renal failure
109. Acute renal failure
110. Prevention of Radiographic-contrast-agent-induced reductions in renal function by acetylcysteine
111. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury
112. Therapeutic effect of arginine-glycine-aspartic acid peptides in acute renal injury
113. Nitric oxide in the regulation of renal blood
114. Toxic acute renal failure in the rat: Effects of l-Arginine and N-methyl-l-Arginine on renal function
115. Cytokines and l-arginine in renal injury and repair
116. Heme protein-mediated renal injury: A protective role for 21-aminosteroids in vitro and in vivo
117. Renal function after acute tubular necrosis
118. Long-term follow-up of renal function and histology after acute tubular necrosis
119. Regeneration after acute tubular necrosis
120. Mechanisms of ischemic acute renal failure
121. The growth hormone Insulin-like growth factor axis in kidney revisited
122. Epidermal growth factor enhances renal tubular cell regeneration and repair and accelerates the recovery of renal failure
123. Epidermal growth factor accelerates functional recovery from ischemic acute tubular necrosis in the rat: Role of epidermal growth factor receptor
124. Insulin-like growth factor-1 accelerates recovery from ischemic acute tubular necrosis in the rat
125. Epidermal growth factor accelerates renal repair in a model of gentamicin nephrotoxicity in rats
126. Rat model for the clinical use of insulin-like growth factor-1 in acute renal failure
127. Preservation of renal function in juxtarenal and suprarenal abdominal aortic aneurysm repair
128. Insulin-like growth factor-1 preserves renal function post-operatively
129. Chiro Study Group: Lack of effect of recombinant human insulin-like growth factor-1 in patients with acute renal failure